Thanks a lot. So the information is up to the date. They are small team, three or four persons actually who are doing the work on behalf of the company.
They need to deal with statisticians, steering committee, advisory board, independent KOLs, RAs (particularly FDA) at this everything is nothing but Covid vaccine period.
They may aim not only a home run, maybe two (nGBM and rGMB), but also other important issues.
It's easy to release TLD as it is available which would be at least one month ago, but it's better to resolve all the quires, possibilities, any unclear/contradictory data sets if existing before releasing TLD.
And they are also dealing with journal publication, warrant holders (Linda herself is a big part of it), maybe some buyout, partnership inquires or negotiation.
Based on what we have known and have expressed in this board repeatedly, I am quite certain we will at least get some kind of approval of DCVax-L for commercial use.
Like TD trader, and some others, I am all in as well. For the life of investing, sometimes one has to go against the rule of thumb, ie, the so-called diversification.
News 
Market Data 
Discover 
AI
